In Conversation With Rea Dabelic, PhD, Senior Market Development Manager in Immunology, 10x Genomics

We sat down with the Co-director of Yale Genome Editing Centre of Yale University, Xiaojun Xing, to discuss his breakthrough cryopreservation method and his thoughts on the genome editing landscape.

Our February discussion group bought together more than 40 key opinion leaders to debate the future of spatial biology. Spatial transcriptomics, single cell resolution and tissue preparation were among the key topics raised.

Our February Omics discussion group focused on novel genome editing and how new technologies are being used to tackle the challenges of transitioning to therapeutic use.

In this commentary article, we present Dr Valerie Taly’s insights on the latest research into digital droplet PCR and the potential applications of liquid biopsy in cancer detection.

Presented by Bastiaan Bijl, Head of Business Development, Single Cell Discoveries & Jens Puschhof, Principle Investigator, German Cancer Research Center

The emergence of single-cell sequencing has opened a new field in analytical biological approaches particularly allowing to uncover cell-to-cell heterogeneity of 3D cellular models and preventing incomplete conclusions drawn from bulk cell populations

In Conversation With Mike Koob, Associate Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group, focusing on ‘Using Biomarkers For Clinical Development & Regulatory Approval,’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

How can the industry transform itself with improved biomarkers for clinical development? And what hurdles stand in the way? We sat down with senior representatives from Galapagos, Ohio State University, and Genentech to find out more.

Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials.

Due to the heterogeneity seen in both eukaryotic and prokaryotic cell populations, single cell analysis opens up many new possibilities.